In July 2025, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) expanded its rare disease pipeline by acquiring REV102, an oral ENPP1 inhibitor for hypophosphatasia (HPP), a disorder with no existing oral ...

CEO Christopher Gibson was one of those sellers, with a Thursday reveal that he had sold 40,390 shares of Recursion's common ...

Beyond big projects, doing smaller, focused exercises is super helpful. GeeksforGeeks has tons of these, covering everything ...